Synopulse

Transforming life sciences with cutting-edge financial insights and valuation solutions. Empowering M&A and business development with precision data.

[Synopulse @synopulse]

NICE draft guidance would have cosmetic surgeons, dentists, and dermatologists screen for body dysmorphic disorder and refer patients rather than proceed.

It cites a 2024 meta-analysis: 18.6% of aesthetic surgery attendees had significant BDD symptoms.

https://t.co/28fbyB4Tdh

[Synopulse @synopulse]

CMS says supplemental rebates under GENEROUS do not change Medicaid Best Price, so they do not affect 340B ceilings.

That is the design choice letting manufacturers offer international prices in Medicaid without repricing anything else in the US.

https://t.co/7tG9G83Cgm

[Synopulse @synopulse]

ICER has published a price benchmark for AbbVie's tavapadon in Parkinson's: $4,764 to $6,861 a year.

The drug is not @FDA -approved, and AbbVie has not named a price. For early Parkinson's, ICER could not calculate a benchmark at all.

https://t.co/ITo0R04MWD

[Synopulse @synopulse]

@NICEComms has recommended Enhertu for HER2-low advanced breast cancer, reversing a rejection.

The evidence did not change. NICE's cost-effectiveness threshold rose in April under the UK and US Pharmaceutical Pricing Agreement.

https://t.co/JvgzUF68UM

[Synopulse @synopulse]

A KRPIA-commissioned survey found Koreans want faster rare-disease reimbursement. Unsurprising, given the sponsor.

The news sits elsewhere. A health ministry director said his staffing has been static for years while the drug regulator got an increase.

https://t.co/NCzhuTEaIB

[Synopulse @synopulse]

Saudi Arabia's SFDA has approved denecimig for haemophilia A, saying it is the first regulator globally to do so.

One of the four Phase 3 studies is a safety-only switch from emicizumab. That tells you who the commercial target is.
https://t.co/YEhnPtIGdm

[Synopulse @synopulse]

@Roche is paying Dualitas $36.5 million upfront, against up to $1 billion, to functionally screen more than 300,000 bispecific antibody combinations. https://t.co/1WD1Cb8E74

[Synopulse @synopulse]

@novonordisk and Orbis Medicines announced a macrocycle discovery deal worth up to $1.4 billion. The release does not separate the upfront payment from the milestones. Dualitas disclosed $36.5m of the $1bn with Roche the same day. https://t.co/gLCF9SKLGt

[Synopulse @synopulse]

At WCLC, two B7-H3 ADC trials in relapsed small-cell lung cancer both returned an OS hazard ratio of 0.46.

In first-line NSCLC, DESTINY-Lung04 came in at OS HR 1.15 and EVOKE-03 at 1.07. Same class of molecule, opposite directions. https://t.co/mG7vH2FA67

[Synopulse @synopulse]

Brown researchers report that axon targeting is set by a genetic switch in the neuron's cell body, not at the growing tip.

Regeneration can already make axons grow. This is about why they arrive in the wrong place. Rodent embryos, observational. https://t.co/G6yPjXwCqE

[Synopulse @synopulse]

NICE is withdrawing four appraisals for dapagliflozin because it is off patent, folding it into a class-level SGLT-2 recommendation.

The withdrawal is a routing decision with no appeal. The updates to on-patent products do carry appeal rights.

https://t.co/9ZejtugGOX

[Synopulse @synopulse]

CMS is adding heart failure, COPD, substance use disorder, and tobacco tracks to its ACCESS Model starting in spring 2027. Payers covering 165 million Americans pledged to align with it.
https://t.co/42qmUamWgP

[Synopulse @synopulse]

Every radiopharma platform buyout since 2023 has cleared 87%. Three of the four cleared 97%.

We went through 238 radiopharmaceutical transactions from 2010 to September 2026. https://t.co/f0lXJ6sDG4

[Synopulse @synopulse]

The UK's AI in healthcare commission has proposed L-plates for new models: supervised clinical deployment before full authorisation, then continuous monitoring for the device's working life.

Point-in-time approval would go. None of it is policy yet. https://t.co/WrwhXrqzMO

[Synopulse @synopulse]

Lilly confirmed it miscalculated the rezpeg efficacy data it presented at EADV in 2022. Every correction favours the drug.

A San Francisco jury is now hearing Nektar's claim that it cost close to $1 billion. No verdict yet.
https://t.co/Zi2jZVvjkB

[Synopulse @synopulse]

@FDA approved Telix's Pixclara for glioma imaging, the first FET-PET product available in the US.

NCCN and the joint European and American societies already recommended FET-PET for this. The recommendation existed; the product did not.
https://t.co/gyognM192I

[Synopulse @synopulse]

Thirty companies, one quarter.

J&J's oncology franchise grew $181M more than STELARA lost. @Novartis ran the same test and missed by $14M.

@Roche grew 6% at constant rates and reported a decline. @TakedaPharma shrank and reported growth.

https://t.co/82IOyZesIC

[Synopulse @synopulse]

Korea adds the Pergoveris pen to national insurance reimbursement from 1 September for all three strengths. The vial was already covered, and the indication is unchanged. This is a device listing, not an eligibility expansion. That happened in April 2025.

https://t.co/lUhgWXkNzy

[Synopulse @synopulse]

Canada's Drug Agency has recommended public reimbursement for Leqembi after a reconsideration. Neither Eisai nor Biogen says what the first recommendation was.

pCPA negotiations come next, followed by 13 separate provincial and territorial decisions.
https://t.co/FLuMbbK2vL

[Synopulse @synopulse]

Nine more MFN agreements take the total to 26 manufacturers and 89% of the branded market.

Not one member of the mid-sized biotech coalition formed to contest MFN is among them. The round was aimed at that group, and the coalition held.

https://t.co/MNxuxAKqxd